Moderna to Test Coronavirus Vaccine Booster Shot in New Clinical Trial

The first jab of Moderna's (NASDAQ: MRNA) two-shot coronavirus vaccine hasn't made it into the arms of the millions who will eventually receive it, but the company is already planning to gauge the effectiveness of a booster. In a presentation at this year's annual J.P. Morgan Healthcare Conference, Moderna said it plans to do so in a clinical trial involving participants of earlier studies of the vaccine, mRNA-1273. In the planned study, Moderna will try to determine the level of immune response still being generated by the booster shot, CEO Stephane Bancel said at the event.